Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: CHMP Positive Opinion Briviact Paediatric

UCB receives CHMP positive opinion for adjunctive use of BRIVIACT® as paediatric treatment for epilepsy patientsCHMP positive opinion for BRIVIACT® brivaracetam extends therapeutic indication to include adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy from 4 years of age.1Epilepsy is the most common serious... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: Cimzia FDA approval psoriasis

UCB Announces the Approval of CIMZIA® certolizumab pegol for ModeratetoSevere Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.The U.S. Food and Drug Administration’s FDA approval of CIMZIA® certolizumab pegol for use in moderatetosevere plaque psoriasis marks the entry of UCB into immunodermatologyCIMZIA Phase 3 psoriasis studies demonstrated significant and... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: U.S. Court of Appeals confirms val idity of patent for UCB's Vimpat®

U.S. Court of Appeals confirms validity of patent for UCBs Vimpat®Court of Appeals for the Federal Circuit affirms Delaware District Court’s decisionBrussels Belgium, May 23rd, 2018 – 18.00 CEST – UCB announces that in a decision released today, the Court of Appeals for the Federal Circuit CAFC has affirmed the Delaware District Court and confirmed the validity of U.S. patent RE38,551... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: Epilepsy as Global Health Priority

UCB joins with ILAE and IBE to encourage World Health Assembly members to continue recognition of epilepsy as global health prioritySignificant gaps in epilepsy management, awareness, and effective treatment access continue around the worldGroups are launching a call to action for public and private engagement to join the fight against Epilepsy through a sustained commitment towards the... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: Cimzia Non-Radiographic Axial Spondyloarthritis Study

CIMZIA® certolizumab pegol is The First Therapy to Demonstrate Positive Results in a 52week, Placebo Controlled NonRadiographic Axial Spondyloarthritis StudyPositive top line results from Phase 3 CAXSPAND study underscore the potential of CIMZIA for nonradiographic axial spondyloarthritis nraxSpA, and provide concrete evidence for the high burden of the disease and limitations of current... See more